ePrints

Thrombolytics and Myocardial Infarction

Lookup NU author(s): Professor Vijay KunadianORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Coronary artery disease is the single leading cause of death in the United States. Occlusion of the coronary artery was identified to be the cause of myocardial infarction almost a century ago. Following a series of investigations, streptokinase was discovered and demonstrated to be beneficial for the treatment of patients with acute myocardial infarction in terms of reducing short- and long-term mortality. Newer agents including tissue plasminogen activators such as alteplase, reteplase, tenecteplase were developed subsequently. In the present era, thrombolytic therapy and primary percutaneous coronary intervention has revolutionized the way patients with acute myocardial infarction are managed resulting in significant reduction in cardiovascular death. This article provides an overview of the various thrombolytic agents utilized in the management of patients with acute myocardial infarction.

Publication metadata

Author(s): Kunadian V, Gibson CM

Publication type: Article

Publication status: Published

Journal: Cardiovascular Therapeutics

Year: 2012

Volume: 30

Issue: 2

Pages: e81-e88

Print publication date: 11/11/2010

ISSN (print): 1755-5914

ISSN (electronic): 1755-5922

Publisher: Wiley-Blackwell Publishing Ltd.

URL: http://dx.doi.org/10.1111/j.1755-5922.2010.00239.x

DOI: 10.1111/j.1755-5922.2010.00239.x

Altmetrics

Share